Asuka Pharmaceutical Holdings has formulated the long-term vision “ASKA VISION 2035” looking ahead to 2035 and the “Medium-Term Management Plan 2028” for the three years starting fiscal 2026, targeting net sales of 85 billion yen and an operating income margin of 10%.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-03-23","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/03\/4886-20260323-01.pdf","jir_short_summary":"Asuka Pharmaceutical Holdings has formulated the long-term vision \"ASKA VISION 2035\" looking ahead to 2035 and the \"Medium-Term Management Plan 2028\" for the three years starting fiscal 2026, targeting net sales of 85 billion yen and an operating income margin of 10%.","jir_summary":"### Long-Term Vision \"ASKA VISION 2035\"\nAsuka Pharmaceutical Holdings has formulated the long-term vision \"ASKA VISION 2035\" looking ahead to 2035, aiming for sustainable growth and social contribution. Leveraging its foundation in the prescription pharmaceutical business primarily focused on obstetrics and gynecology, the company will strengthen drug discovery research, expand overseas operations, and develop animal health, diagnostic, and around-the-pill businesses. It clarifies its purpose, vision, and mission to provide value to stakeholders.\n\n### Overview of the Medium-Term Management Plan 2028\nThe \"Medium-Term Management Plan 2028,\" covering fiscal years 2026 through 2028, represents the first phase of execution toward realizing the long-term vision. The financial targets include net sales of 85 billion yen, operating income margin of 10%, ROE of 10%, and total payout ratio of 40%. Business strategies focus on strengthening the prescription pharmaceutical business, expanding the business portfolio, and advancing overseas operations. Financial strategies emphasize optimizing cash allocation and considering agile share buybacks. To strengthen management foundations, the company will promote next-generation talent development, ESG initiatives, and digital transformation (DX).","jir_financial_highlights":"Net Sales: 85 billion yen (Unknown)\nOperating Income Margin: 10% (Unknown)\nROE: 10% (Unknown)\nTotal Payout Ratio: 40% (Unknown)","jir_category":"","jir_hashtags":"#AsukaPharmaceuticalHoldings, #MediumTermManagementPlan, #LongTermVision, #ASKAVISION2035, #JapaneseStocks","jir_key_figures":"Net sales target: 85 billion yen (Fiscal 2028)\nOperating income margin target: 10% (Fiscal 2028)\nROE target: 10% (Fiscal 2028)","jir_meta_title":"Asuka Pharmaceutical Formulates 2035 Long-Term Vision and 2028 Medium-Term Management Plan Targeting 85 Billion Yen in Net Sales","jir_meta_description":"Asuka Pharmaceutical Holdings announces its long-term vision \"ASKA VISION 2035\" and medium-term management plan through 2028, aiming for net sales of 85 billion yen and an operating income margin of 10%, promoting sustainable growth and social contribution.","jir_og_title":"Asuka Pharmaceutical Formulates 2035 Long-Term Vision and 2028 Medium-Term Plan","jir_og_description":"Asuka Pharmaceutical Holdings announces its long-term vision for 2035 and medium-term plan through 2028, setting targets of 85 billion yen in net sales and 10% operating income margin.","jir_og_image_url":"\/assets\/og\/company-business_update.jpg","jir_chart_data_collection":"[]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"business_update","footnotes":""},"sector":[],"importance":[],"class_list":["post-35737","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n